comparemela.com

Latest Breaking News On - Kineta chart - Page 1 : comparemela.com

Kineta Announces Restructuring and Exploration of Strategic Alternatives

29.02.2024 - SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) - Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has . Seite 1

Shawn iadonatoPauline kennyKineta incChief executive officerGeneral counselKineta chartIneta kursIneta aktie

Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial

03.10.2023 - Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level

Shawn iadonatoKineta incChief executive officerKineta chartIneta kursIneta aktie

Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

25.09.2023 - SEATTLE, Sept. 25, 2023 (GLOBE NEWSWIRE) - Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will . Seite 1

United statesThierry guillaudeuxKineta incAmerican association for cancer researchAmerican associationCancer researchSpecial conferenceTumor immunologyChief scientific officerPoster sessionMetropolitan ballroomKineta chartIneta kursIneta aktie

vimarsana © 2020. All Rights Reserved.